Otsuka Holdings Co Ltd
TSE:4578

Watchlist Manager
Otsuka Holdings Co Ltd Logo
Otsuka Holdings Co Ltd
TSE:4578
Watchlist
Price: 8 910 JPY -0.47% Market Closed
Market Cap: 4.8T JPY
Have any thoughts about
Otsuka Holdings Co Ltd?
Write Note

Otsuka Holdings Co Ltd
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Otsuka Holdings Co Ltd
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Otsuka Holdings Co Ltd
TSE:4578
Gross Profit
ÂĄ1.6T
CAGR 3-Years
18%
CAGR 5-Years
12%
CAGR 10-Years
4%
Takeda Pharmaceutical Co Ltd
TSE:4502
Gross Profit
ÂĄ3T
CAGR 3-Years
8%
CAGR 5-Years
10%
CAGR 10-Years
9%
Daiichi Sankyo Co Ltd
TSE:4568
Gross Profit
ÂĄ1.3T
CAGR 3-Years
26%
CAGR 5-Years
18%
CAGR 10-Years
9%
S
Shionogi & Co Ltd
TSE:4507
Gross Profit
ÂĄ358.7B
CAGR 3-Years
15%
CAGR 5-Years
-8%
CAGR 10-Years
6%
Chugai Pharmaceutical Co Ltd
TSE:4519
Gross Profit
ÂĄ805.2B
CAGR 3-Years
11%
CAGR 5-Years
15%
CAGR 10-Years
13%
Astellas Pharma Inc
TSE:4503
Gross Profit
ÂĄ1.7T
CAGR 3-Years
18%
CAGR 5-Years
11%
CAGR 10-Years
7%
No Stocks Found

Otsuka Holdings Co Ltd
Glance View

Market Cap
4.8T JPY
Industry
Pharmaceuticals

Otsuka Holdings Co., Ltd. is a Japanese pharmaceutical and nutraceutical powerhouse, woven into the fabric of global health and wellness. Founded in 1964, the company has consistently focused on the discovery, development, and commercialization of innovative products aimed at tackling unaddressed medical needs. Otsuka's broad portfolio includes prescription drugs, particularly in the areas of psychiatry, neurology, and oncology, complemented by a robust range of consumer healthcare products such as drinks and nutritional supplements. With a commitment to research and development, the company invests significantly in innovative drug solutions, resulting in a legacy marked by breakthroughs such as Abilify, a treatment for schizophrenia and bipolar disorder, and an array of lifestyle products that support overall well-being. For investors, Otsuka Holdings presents an intriguing blend of stability and growth potential. Its diversified business model mitigates dependence on any single market segment. The company’s strong financial foundation, supported by solid revenue from both its pharmaceutical and consumer health divisions, highlights its resilience even in challenging economic conditions. As Otsuka continues to expand its global footprint, particularly in emerging markets and through strategic partnerships, it positions itself to capitalize on the growing demand for innovative therapies and nutritional products. The company’s robust commitment to sustainability and social responsibility further enhances its attractiveness to investors looking for long-term value. With a vision centered on health, innovation, and quality of life, Otsuka stands as a formidable player in the healthcare landscape, poised for growth while delivering on its mission to create new products for a healthier world.

Intrinsic Value
9 473.82 JPY
Undervaluation 6%
Intrinsic Value
Price

See Also

What is Otsuka Holdings Co Ltd's Gross Profit?
Gross Profit
1.6T JPY

Based on the financial report for Sep 30, 2024, Otsuka Holdings Co Ltd's Gross Profit amounts to 1.6T JPY.

What is Otsuka Holdings Co Ltd's Gross Profit growth rate?
Gross Profit CAGR 10Y
4%

Over the last year, the Gross Profit growth was 19%. The average annual Gross Profit growth rates for Otsuka Holdings Co Ltd have been 18% over the past three years , 12% over the past five years , and 4% over the past ten years .

Back to Top